CYTK · Cytokinetics Inc · Webcasts, Transcripts & Audio
$51.65
-1.52 (-2.86%)
At close · Nov 17
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$7.20B
Shares
139.30M
Volume · Nov 17
2.71M
Avg daily vol (3M)
2.01M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Cytokinetics Inc Webcasts
Earnings calls, investor updates, investor days and conferences for Cytokinetics Inc (CYTK), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Conference
Investor event
2026-11-30
Cytokinetics Inc (CYTK) November 30, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-11-17
Cytokinetics Inc (CYTK) November 17, 2026 Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-11-16
Cytokinetics Inc (CYTK) November 16, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-11-10
Cytokinetics Inc (CYTK) November 10, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-11-04
Cytokinetics Inc (CYTK) Q3 2026 Earnings Call Transcript
Confident tone
Mycorso U.S. commercial launch
Acacia HCM and potential NHCM launch
International expansion
Revenue
$47.56M
▲ 2356.5% YoY Diluted EPS
$-1.37
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-14
Cytokinetics Inc (CYTK) September 14, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-09
Cytokinetics Inc (CYTK) September 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-06
Cytokinetics Inc (CYTK) Q2 2026 Earnings Call Transcript
Confident tone
Mycorso U.S. commercial launch momentum
Aficampten NHCM label expansion (Acacia-HCM)
Regulatory and FDA interactions (priority review)
Revenue
$28.62M
▼ 57.1% YoY Diluted EPS
$-1.50
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-08
Cytokinetics Inc (CYTK) June 8, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-03
Cytokinetics Inc (CYTK) June 3, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-19
Cytokinetics Inc (CYTK) May 19, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-05
Cytokinetics Inc (CYTK) Q1 2026 Earnings Call Transcript
Confident tone
Acacia HCM Phase 3 results
MYCorzo U.S. commercial launch
Financial performance and guidance
Revenue
$19.36M
▲ 1125.8% YoY Diluted EPS
$-1.67
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-04-13
Cytokinetics Inc (CYTK) April 13, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-03-11
Cytokinetics Inc (CYTK) March 11, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-02-24
Cytokinetics Inc (CYTK) Q4 2025 Earnings Call Transcript
Confident tone
MYCorzo U.S. commercial launch
Regulatory approvals and global expansion
ACACIA-HCM in non-obstructive HCM
Revenue
$17.75M*
▲ 4.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-05
Cytokinetics Inc (CYTK) Q3 2025 Earnings Call Transcript
Confident tone
Pipeline programs beyond aficamten
FDA approval and launch readiness for aficamten
Nonobstructive HCM (nHCM) opportunity
Revenue
$1.94M
▲ 318.1% YoY Diluted EPS
$-2.55
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Cytokinetics Inc (CYTK) Q2 2025 Earnings Call Transcript
Confident tone
ACACIA-HCM in non-obstructive HCM
Heart failure pipeline (omecamtiv mecarbil / ulacamten)
FDA regulatory review of aficamten (PDUFA extension)
Revenue
$66.77M
▲ 26714.9% YoY Diluted EPS
$-1.12
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Cytokinetics Inc (CYTK) Q1 2025 Earnings Call Transcript
Positive tone
Aficamten oHCM NDA approval
FDA REMS and PDUFA extension
ACACIA-HCM nHCM pivotal trial
Revenue
$1.58M
▲ 89.1% YoY Diluted EPS
$-1.36
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Cytokinetics Inc (CYTK) Q4 2024 Earnings Call Transcript
Confident tone
Commercial readiness and U.S. launch
International partnerships
Pipeline diversification
Revenue
$16.93M*
▲ 912.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-09-30
Date not confirmed
Cytokinetics Inc (CYTK) Q3 2024 Earnings Call Transcript
Confident tone
Pipeline diversification beyond aficamten
Aficamten NDA submission and FDA review
Earlier-stage pipeline and neuromuscular programs
Revenue
$463,000
▲ 22.5% YoY Diluted EPS
$-1.36
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Cytokinetics Inc (CYTK) Q2 2024 Earnings Call
Revenue
$249,000
▼ 71.3% YoY Diluted EPS
$-1.31
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Cytokinetics Inc (CYTK) Q1 2024 Earnings Call Transcript
Confident tone
Aficamten pivotal data and presentations
Commercial readiness for launch
Regulatory submissions and FDA engagement
Revenue
$835,000
▼ 81.9% YoY Diluted EPS
$-1.33
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-27
Cytokinetics Inc (CYTK) Q4 2023 Earnings Call Transcript
Confident tone
SEQUOIA-HCM Phase 3 results
Additional aficamten clinical trials
Pipeline beyond aficamten
Revenue
$1.67M*
▼ 14.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Cytokinetics Inc (CYTK) Q3 2023 Earnings Call Transcript
Revenue
$378,000
▼ 85% YoY Diluted EPS
$-1.35
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Cytokinetics Inc (CYTK) Q2 2023 Earnings Call Transcript
Revenue
$867,000
▼ 99% YoY Diluted EPS
$-1.34
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Cytokinetics Inc (CYTK) Q1 2023 Earnings Call Transcript
Revenue
$4.61M
▲ 301.8% YoY Diluted EPS
$-1.38
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-01
Cytokinetics Inc (CYTK) Q4 2022 Earnings Call Transcript
Revenue
$1.96M*
▼ 96.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Cytokinetics Inc (CYTK) Q3 2022 Earnings Call Transcript
Revenue
$2.52M
▼ 53.7% YoY Diluted EPS
$-1.52
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Cytokinetics Inc (CYTK) Q2 2022 Earnings Call Transcript
Revenue
$88.97M
▲ 3029.4% YoY Diluted EPS
$-0.23
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Cytokinetics Inc (CYTK) Q1 2022 Earnings Call Transcript
Revenue
$1.15M
▼ 82.5% YoY Diluted EPS
$-1.05
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-24
Cytokinetics Inc (CYTK) Q4 2021 Earnings Call Transcript
Revenue
$55.60M*
▲ 727.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-03
Cytokinetics Inc (CYTK) Q3 2021 Earnings Call Transcript
Revenue
$5.44M
▼ 87% YoY Diluted EPS
$-0.95
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Cytokinetics Inc (CYTK) Q2 2021 Earnings Call Transcript
Revenue
$2.84M
▼ 20.9% YoY Diluted EPS
$-0.86
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Cytokinetics Inc (CYTK) Q1 2021 Earnings Call Transcript
Revenue
$6.55M
▲ 71.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-25
Cytokinetics Inc (CYTK) Q4 2020 Earnings Call Transcript
Revenue
$6.72M*
▲ 29% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-04
Cytokinetics Inc (CYTK) Q3 2020 Earnings Call Transcript
Revenue
$41.69M
▲ 588.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Cytokinetics Inc (CYTK) Q2 2020 Earnings Call Transcript
Revenue
$3.59M
▼ 49.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-04-14
Cytokinetics Inc (CYTK) Q1 2020 Earnings Call Transcript
Revenue
$3.83M
▼ 54.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–38 of 38 webcasts
Key facts
CIK
1061983
CUSIP
23282W605
13F (30d)
489 filings
451 filers
Visit website
Investor relations